Novel Monoclonal Antibody Reduces Bleeds in Hemophilia A and B

(MedPage Today) -- SAN DIEGO -- The investigational monoclonal antibody marstacimab reduced the rate of treated bleeds in patients with hemophilia A or B without inhibitors to factor VIII or factor IX, the phase III BASIS trial showed. The annualized...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news